ACTIN Report (research use only)

PATIENT
EXAMPLE-CRC-01

REPORT DATE
17-Sep-2025

Gender: Female | Birth year: 1946 | WHO: 0

Tumor: Colorectum (cecum) carcinoma | Lesions: Lung, Peritoneal | Stage: IV

Clinical summary

Gender (birth year, WHO)	**Female (1946, WHO 0)**	Stage	**IV**
Tumor	**Colorectum (cecum) carcinoma**	DPYD	**N/A**
Lesions	**Lung, Peritoneal**	UGT1A1	**N/A**
Measurable (RECIST)	**Yes**		

Relevant systemic treatment history	**None**	
Relevant other oncological history	**11/2021**	**Hemicolectomy right (Cecum)**
Previous primary tumor	**Skin squamous cell carcinoma (diagnosed 6/2016, last treatment 8/2016, considered non-active)**	
Relevant non-oncological history	**1/2019**	**Cerebrovascular accident**
Recent molecular results	**[KRAS G12D (0.0/0.0 copies), NRAS: No reportable events, BRAF: No reportable events, HER2: No reportable events], MSS**	

Standard of care options considered potentially eligible

Treatment	Literature efficacy evidence	Real-world efficacy evidence	Warnings
FOLFIRI	PHASE-3-CRC		
	PFS: 10.0 months (95% CI: 10.0-12.0)	**PFS:** 13.3 months, IQR: 12.6	
	OS: 25.0 months (95% CI: 25.0-30.0)	**OS:** 22.2 months, IQR: 24.8	

Trials in NL that are open and potentially eligible (1 cohort from 1 trial)

Trial	Cohort	Molecular	Sites	Warnings
KRAS-G12D-TRIAL	*KRAS G12D*	*KRAS G12D*	*UMC Utrecht*	

Trials matched solely on molecular event and tumor type (no clinical data used) are shown in italicized, smaller font.

SOC personalized real-world evidence annotation

Treatment decisions (percentage of population assigned to systemic treatment) in NCR real-world data set

	All (n=9207)	Age 73-83y (n=2727)	WHO 1 (n=2828)	RAS positive (n=2760)	Liver only lesions (n=2715)
FOLFIRI	38.5%	23.8%	37.9%	44.6%	39.5%

Median overall survival (OS) in months in NCR real-world data set

	All (n=9207)	Age 73-83y (n=2727)	WHO 1 (n=2828)	RAS positive (n=2760)	Liver only lesions (n=2715)
FOLFIRI	**16.1**, IQR: 18.2 (n=3543)	**15.4**, IQR: 18.2 (n=649)	**14.8**, IQR: 16.3 (n=1071)	**15.8**, IQR: 14.2 (n=1230)	**16.5**, IQR: 17.4 (n=1073)

Median progression-free survival (PFS) in months in NCR real-world data set

	All (n=5018)	Age 73-83y (n=1330)	WHO 1 (n=1623)	RAS positive (n=1822)	Liver only lesions (n=1534)
FOLFIRI	**8.2**, IQR: 5.5 (n=2106)	**8**, IQR: 6.1 (n=340)	**7.9**, IQR: 5 (n=661)	**8**, IQR: 4.7 (n=836)	**8.3**, IQR: 5.3 (n=652)

Explanation:

These tables only show treatments that are considered standard of care (SOC) in colorectal cancer in the Netherlands.

The ‘All’ column shows results in NCR patients who were previously untreated, diagnosed with colorectal cancer with distant metastases and treated systemically without surgery, for whom the treatment could be categorized in SOC treatments.

The ‘Age’, ‘WHO’, ‘RAS’ and ‘Lesions’ columns show results based on patients from the ‘All’ population, filtered for equal WHO, similar age, equal RAS status or equal lesion localization, respectively.

‘PFS’ is calculated as the duration from the date on which the first compound of the treatment was administered, until first progression.

‘OS’ is calculated as the duration from the date on which the first compound of the treatment was administered, until death from any cause.

When patient number is too low (n <= 20) to predict PFS or OS, "NA" is shown.







ACTIN Report (research use only)

PATIENT
EXAMPLE-CRC-01

REPORT DATE
17-Sep-2025



Resistance evidence

Resistance evidence

Treatment	Mutation	Evidence source	Evidence level	Found in molecular analysis
FOLFIRI	GENE S11C	[1]	D	Yes

SOC literature efficacy evidence

Standard of care options considered potentially eligible

The following standard of care treatment(s) could be an option for this patient. For further details per study see 'SOC literature details' section in extended report.

Treatment	Literature efficacy evidence
FOLFIRI	PHASE-3-CRC

Patient characteristics:

WHO/ECOG	0: 100, 1: 80, 2: 20, 3: 0, 4: 0
Primary tumor location	Left: 145, Both or unknown: 10, Right: 45
Mutations	KRAS exon 2 wild-type 200/200
Metastatic sites	Liver only: 58 (32.0%), Lung only: 10 (6.0%)
Previous systemic therapy	35/200
Prior therapies	Adjuvant chemotherapy

Median PFS: 10.0 months (95% CI: 10.0-12.0)

Median OS: 25.0 months (95% CI: 25.0-30.0)

Clinical Details

Clinical summary

Relevant systemic treatment history	**None**	
Relevant other oncological history	**11/2021**	**Hemicolectomy right (Cecum)**
Previous primary tumor	**Skin squamous cell carcinoma (diagnosed 6/2016, last treatment 8/2016, considered non-active)**	
Relevant non-oncological history	**1/2019**	**Cerebrovascular accident**

Patient current details (05-Mar-2023)

Unresolved toxicities grade => 2	**None**
Cancer-related complications	**Unknown**
Known allergies	**Morphine**
Recent surgeries	**12-Nov-2021 Hemicolectomy right**

Tumor details (05-Mar-2023)

Measurable disease	**Yes**
Known lesions	**Lung, Peritoneal**
Unknown lesions	**Lymph node**
No lesions present	**CNS, Brain, Liver, Bone**

Active medication details

Medication	Administration route	Start date	Stop date	Dosage	Frequency
None					

Blood transfusions

Product	Date
ERTHROCYTES_FILTERED	10-Jan-2023

Other Trial Matching Results

Trials and cohorts that are potentially eligible, but are closed (0)

Trial	Cohort	Molecular	Sites	Warnings
None				

Trials and cohorts that are considered ineligible (2)

Trial	Cohort	Molecular	Ineligibility reasons
METC 02 KAYRAS	*Applies to all cohorts below*	KRAS G12D	PD-L1 expression below minimum of 50.0
	Dose expansion - monotherapy - Colorectum		
	Dose expansion - monotherapy - NSCLC		No lung non-small cell carcinoma

Trials and cohorts that are not evaluable or ignored (0)

Trial	Cohort	Molecular	Sites	Configuration
None				